Number of news items returned: 181 to 200 records of 375

Australian Trading and Investment Corporation update: New Team, New Home & Bigger Plans!

23 October 2015


"Successfully launches a limited Convertible Note offering US Fund Manager and Australian Small Cap Equity Fund Manager join the Management Board The ...

Queensland Premier names Opmantek as Queensland's Leading ICT Exporter and Innovator

23 October 2015


"Opmantek (ASSOB:OMK) has been acknowledged by Queensland Premier Annastacia Palaszczuk for innovation, leadership and for being QLD’s leading ICT exporter ...

Ocular Robotics Issues Supplementary Offer Document

19 October 2015


"The Company has issued a Supplementary Offer Document, dated 17th October 2015 in order to provide investors with an update ...

CRe8 Home & Finance: Cornerstone $1m Investor and Trading Halt Update

15 October 2015


"To Whom It May Concern: We are very pleased and excited to announce that CRe8 Home and Finance Ltd (CRe8) has ...

Opmantek (ASSOB:OMK) has been acknowledged by Queensland Premier Annastacia Palaszczuk

14 October 2015


The NewsMaker website has published the following article about Opmantek, today October 14th, 2015:   "BRISBANE, QLD – Opmantek (ASSOB:OMK) has been ...

Policy Hack: Marketing of share offers under non-disclosure

10 October 2015


Marketing of share offers under non-disclosure. The current regulations allow property and business for sale to be widely advertised and ...

Significant Commercial Agreement - Trading Halt CRe8 Home and Finance Limited (ASSOB: CHF)

08 October 2015


"CRe8 has signed a significant commercial agreement, which in the Directors’ opinions materially enhances the value of the company. CRe8 ...

Ocular Robotics: Australian Robotics Company a Game Changer in Silicon Valley

28 September 2015


  "Ocular Robotics has been recognised as a game changer in the global robotics revolution. The Next Generation Game Changer Award ...

Funding Strategies Connect - September 2015

24 September 2015


Dear Readers, This month I am delighted to share updates from YDF, CRe8, ATIC, Mandala, Opmantek, Ocular Robotics and Squirel with ...

YDF Holdings reaches minimum subscription, launches on ASSOB's primary board

17 September 2015


"Your Digital File (ASSOB: YDF) is thrilled to announce that the Company’s capital raise has reached minimum subscription and the ...

Squirel completes capital raising

16 September 2015


"Squirel Ltd (“Squirel” or the “Company”) (ASSOB: SQU) is pleased to announce the suspension of it’s capital raising campaign and ...

The BioCube Corporation: Feronia signs agreement to purchase first Biocube for Africa

15 September 2015


The BioCube Corporation website published the following article on September 15th, 2015:   "The BioCube Corporation confirms Feronia Inc., an agribusiness operating ...

Ocular Robotics selected to meet with ABB Robotics CEO, captures 3D scenes in Japan, technology to assist firefighters

09 September 2015


  " Ocular Robotics selected for meeting with ABB Robotics CEO In August OCR participated in a competition run by UK Company Idea ...

Opmantek signs major deal with North American Fortune 50 Company

08 September 2015


"Opmantek Ltd (ASSOB: OMK) are excited to announce a signed contract with a preeminent North American Fortune 50 company to ...

Australian Trading & Investment Corporation - Free Trial Offer

08 September 2015


"Greetings… My name is Daniel Hendry (CEO: Australian Trading & Investment Corporation), and below is a summarized update on the company ...

Private Equity - Size Matters

08 September 2015


"One of the common differences of between public and private firms is size. More often than not, the investment opportunities ...

Mandala Announces Acquisition of Two Properties

03 September 2015


"Mandala Asset Solutions Pty Limited as manager of the Trinity Accommodation Regional Hospitality Fund (TARHF) is delighted to announce the ...

Two key milestones for Your Digital File in August

31 August 2015


"August included two key milestones for Your Digital File: The launch of Pilot programs in the legal and educational sectors Our new ...

Uchoose confirms 6th consecutive quarter of sales growth and welcomes leading industry authority to advisory role.

31 August 2015


"Uchoose is pleased to announce its 6th consecutive quarter of growth in sales for April-June and to coincide with this ...

Private Funding

29 August 2015


Looking for Private Funding to grow your business?  We can assist with your financing strategy whether it being to raise ...

JNCI publication involving CytImmune's CYT-21625

10 March 18


"JNCI publication involving CytImmune's CYT-21625"


"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.

Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "


David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents